Evommune, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(c) Rule 10b5-1 Trading Plans
During the fiscal quarter ended March 31, 2026, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
| Type of Trading Arrangement | ||||||
|---|---|---|---|---|---|---|
| Name · Title · Action · Date · Rule 10b5-1* · Non-Rule 10b5-1** · Total Shares of Common Stock to be Sold · Expiration Date | ||||||
| Luis Peña | President and CEO | Adoption | March 2, 2026 | X | 156,225 | March 2, 2027 |
| Kyle Carver | Chief Financial Officer | Adoption | February 26, 2026 | X | 40,675 | February 26, 2027 |
| Eugene Bauer | Chief Medical Officer | Adoption | March 14, 2026 | X | 108,120 | March 14, 2027 |
| Greg Moss | Chief Business and Legal Officer | Adoption | February 26, 2026 | X | 33,437 | February 26, 2027 |
| Jeegar Patel | Chief Scientific Officer | Adoption | February 27, 2026 | X | 33,175 | February 27, 2027 |
| Janice Drew | Chief of Development Operations | Adoption | March 9, 2026 | X | 146,805 | March 9, 2027 |
| David Cohen | Director | Adoption | March 3, 2026 | X | 23,665 | March 3, 2027 |
*Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
**"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
Each trading plan is intended to permit transactions in the Company’s securities at times when the individual may otherwise be in possession of material nonpublic information.
Other than as described above, during the three months ended March 31, 2026, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.